Abiraterone Interactions
Levetiracetam
No clinically significant drug interactions identified.
Levodopa/carbidopa
No clinically significant drug interactions identified.
Levofloxacin
No clinically significant drug interactions identified.
Levothyroxine
No clinically significant drug interactions identified.
Linagliptin
No clinically significant drug interactions identified.
Liraglutide
No clinically significant drug interactions identified.
Lisdexamphetamine
Caution - increased level of lisdexamphetamine due to 2D6 inhibition. Monitor for signs of toxicity (ie. tachycardia, agitation, anxiety). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Lisinopril
No clinically significant drug interactions identified.
Loperamide
No clinically significant drug interactions identified.
Lorazepam
No clinically significant drug interactions identified.
Losartan
No clinically significant drug interactions identified.
Memantine
No clinically significant drug interactions identified.
Methadone
Caution - increased level of methadone due to 2D6 inhibition. Titrate with extreme caution due to risk of overdose. If already established on methadone, may require dose reduction. Consider choosing an alternative agent.
Methylphenidate
No clinically significant drug interactions identified.
Metoclopramide
Caution - increased level of metoclopramide due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Metoprolol
Caution - increased level of metoprolol due to 2D6 inhibition. Monitor for signs of toxicity (ie. hypotension, bradycardia, impotence). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Metrondiazole
No clinically significant drug interactions identified.
Mirabegron
No clinically significant drug interactions identified.
Mirtazapine
No clinically significant drug interactions identified.
Misoprostol
No clinically significant drug interactions identified.
Montelukast
No clinically significant drug interactions identified.
Moxifloxacin
No clinically significant drug interactions identified.
Naltrexone
No clinically significant drug interactions identified.
Naproxen
No clinically significant drug interactions identified.
Nifedipine XL
No clinically significant drug interactions identified.
Nirapirib
No clinically significant drug interactions identified.
Nitrofurantoin
No clinically significant drug interactions identified.
Nortriptyline
Caution - increased level of nortriptyline due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Olanzapine
No clinically significant drug interactions identified.
Olaparib
No clinically significant drug interactions identified.
Omeprazole
No clinically significant drug interactions identified.
Ondansetron
No clinically significant drug interactions identified.
Orlistat
No clinically significant drug interactions identified.
Oxazepam
No clinically significant drug interactions identified.
Oxybutynin
No clinically significant drug interactions identified.
Oxycodone
Caution - increased level of oxycodone due to 2D6 inhibition. Titrate with extreme caution due to risk of overdose. If already established on oxycodone, may require dose reduction. Consider choosing an alternative agent.
Pantoprazole
No clinically significant drug interactions identified.
Paroxetine
Caution - increased level of paroxetine due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Penicillin
No clinically significant drug interactions identified.
Perindopril
No clinically significant drug interactions identified.
Perinodopril
No clinically significant drug interactions identified.
Phenobarbital
Avoid combination - decreased level of abiraterone due to 3A4 induction. Choose an alternative agent.
Phenytoin
Avoid combination - decreased level of abiraterone due to 3A4 induction. Choose an alternative agent.
Pioglitazone
Caution - severe hypoglycemia has been reported when used in combination in patients with pre-existing diabetes. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Pravastatin
Caution - increased level of pravastatin due to OAT1B1 inhibition. Monitor for signs of toxicity (ie. CK). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Prazosin
No clinically significant drug interactions identified.
Prednisone
No clinically significant drug interactions identified.
Pregabalin
No clinically significant drug interactions identified.
Prochlorperazine
No clinically significant drug interactions identified.
Propranolol
Caution - increased level of propanolol due to 2D6 inhibition. Monitor for signs of toxicity (ie. hypotension, bradycardia, impotence). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Quetiapine
No clinically significant drug interactions identified.
Rabeprazole
No clinically significant drug interactions identified.
Ramipril
No clinically significant drug interactions identified.
Ranitidine
No clinically significant drug interactions identified.
Relugolix
No clinically significant drug interactions identified.
Repaglinide
Caution - increased level of repaglinide due to OAT1B1/2C8 inhibition. Monitor for signs of toxicity (ie. hypoglycemia). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Risedronate
No clinically significant drug interactions identified.
Risperidone
Caution - increased level of risperidone due to 2D6 inhibition. Monitor for signs of toxicity (ie. EPS, hyperprolactinemia). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Rivaroxaban
Caution - increased level of rivaroxaban due to potential 3A4 inhibition. Consider choosing an alternative agent.
Rivastigmine
No clinically significant drug interactions identified.
Rizatriptan
No clinically significant drug interactions identified.
Ropinirole
No clinically significant drug interactions identified.
Rosuvastatin
Caution - increased level of rosuvastatin due to OAT1B1 inhibition. Monitor for signs of toxicity (ie. CK). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction.
Saxagliptin
No clinically significant drug interactions identified.
Semaglutide
No clinically significant drug interactions identified.
Senna
No clinically significant drug interactions identified.
Sertraline
No clinically significant drug interactions identified.
Sildenafil
No clinically significant drug interactions identified.
Silodosin
No clinically significant drug interactions identified.
Simvastatin
Caution - increased level of simvastatin due to OAT1B1 inhibition. Monitor for signs of toxicity (ie. CK). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction.
Sitagliptin
No clinically significant drug interactions identified.
Solifenacin
No clinically significant drug interactions identified.
Spironolactone
Avoid combination - increased risk of sub-optimal clinical benefit due to increase in activation of mutant and wild-type androgen receptors in patients receiving abiraterone for treatment of castration-resistant prostate cancer. Choose an alternative agent.
Sulfamethoxazole-trimethoprim
No clinically significant drug interactions identified.
Sumatriptan
No clinically significant drug interactions identified.
Tadalafil
No clinically significant drug interactions identified.
Talazoparib
No clinically significant drug interactions identified.
Tamsulosin
Caution - increased level of tamsulosin due to 2D6 inhibition. Monitor for signs of toxicity (ie. syncope). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Telmisartan
No clinically significant drug interactions identified.
Temazepam
No clinically significant drug interactions identified.
Terazocin
No clinically significant drug interactions identified.
Terazosin
No clinically significant drug interactions identified.
Terbinafine
No clinically significant drug interactions identified.
Ticagrelor
No clinically significant drug interactions identified.
Tolterodine
No clinically significant drug interactions identified.
Topiramate
No clinically significant drug interactions identified.
Tramadol
Caution - increased level of tramadol due to 2D6 inhibition. Titrate with extreme caution due to risk of overdose. If already established on tramadol, may require dose reduction. Consider choosing an alternative agent.
Tramadol-acetaminophen
Caution - increased level of tramadol due to 2D6 inhibition. Titrate with extreme caution due to risk of overdose. If already established on tramadol, may require dose reduction. Consider choosing an alternative agent.
Trazodone
No clinically significant drug interactions identified.
Valacyclovir
No clinically significant drug interactions identified.
Valsartan
No clinically significant drug interactions identified.
Vardenafil
No clinically significant drug interactions identified.
Varenicline
No clinically significant drug interactions identified.
Venlafaxine
No clinically significant drug interactions identified.
Verapamil
No clinically significant drug interactions identified.
Vortioxetine
Caution - increased level of vortioxetine due to 2D6 inhibition. Monitor for signs of toxicity (ie. GI upset, agitation). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Warfarin
Caution - increased level of warfarin due to 1A2/3A4/2C9/2C19 inhibition. Monitor INR more closely after initiation of abiraterone therapy or dose changes. Titrate warfarin dose to target INR.
Zolmitriptan
No clinically significant drug interactions identified.
Zolpidem
No clinically significant drug interactions identified.
Zopiclone
No clinically significant drug interactions identified.
